AstraZeneca (LSE:AZN) has secured acceptance of regulatory filings in Europe and Japan for the TAGRISSO plus ORPATHYS regimen ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
AstraZeneca and Daiichi Sankyo's Enhertu (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with ...
Drugmaker Astrazeneca said on Tuesday that Enhertu has been approved in the European Union as an adjuvant treatment for ...
AstraZeneca (NASDAQ:AZN) and Daiichi Sankyo (OTCPK:DSKYF) announced Tuesday they have withdrawn the EU marketing application for their experimental lung cancer therapy, datopotamab deruxtecan ...
AstraZeneca and Daiichi Sankyo have secured European Union approval for Enhertu as an adjuvant monotherapy for adults with resected HER2-positive early breast cancer who retain residual invasive ...
AstraZeneca (ISIN GB0009895292) secured European Union approval for Enhertu in adjuvant treatment of adults with residual ...
AstraZeneca PLC - Cambridge, England-based pharmaceutical maker - Says Enhertu, developed with Daiichi Sankyo Co Ltd, has been approved in the EU to treat adults with HER2-positive early breast cancer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results